Arlocabtagene autoleucel：一种用于重度预治疗复发/难治性多发性骨髓瘤的靶向 GPRC5D CAR-T 细胞疗法
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
97.0分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
FRONTIER PAPERS
前沿论文 219
条件筛选 · 已选 2 项 · 共 219 条展开收起
适应症
血液
泌尿
皮肤与软组织
靶点
多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸
Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.
84.3分
★★★★☆
站内排序·非疗效
多发性骨髓瘤感染风险增加的免疫生物标志物
Immune biomarkers of increased infection risk in multiple myeloma.
83.9分
★★★★☆
站内排序·非疗效
新诊断多发性骨髓瘤的一线治疗
First-line Therapy in Newly Diagnosed Multiple Myeloma.
79.4分
★★★★☆
站内排序·非疗效
从静态风险到动态疾病监测：MRD 与免疫图谱在多发性骨髓瘤中的作用
From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma.
79.1分
★★★★☆
站内排序·非疗效
多发性骨髓瘤：2026 年诊断、风险分层与管理更新
Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management.
79.1分
★★★★☆
站内排序·非疗效
初诊多发性骨髓瘤老年患者的免疫特征与一线治疗生存结局相关，且与衰弱程度无关
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of
71.9分
★★★★☆
站内排序·非疗效
FDA 批准摘要：Idecabtagene Vicleucel 用于治疗三类暴露、复发/难治性多发性骨髓瘤
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.
70.4分
★★★★☆
站内排序·非疗效
多发性骨髓瘤的新型免疫靶点：生物学意义与治疗潜力
Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.
69.3分
★★★☆☆
站内排序·非疗效
骨髓 NK 细胞谱预测接受 daratumumab 为基础治疗的多发性骨髓瘤患者的 MRD 阴性
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.
68.9分
★★★☆☆
站内排序·非疗效